Ivermectin for Skin Cancer: Topical Ivermectin Success Stories on Skin Cancer (2025)

Introduction

In an era where conventional cancer treatments often come with significant side effects and variable success rates, alternative therapies are gaining attention for their potential accessibility and lower toxicity. This exploration delves into the emerging use of topical ivermectin—a well-established antiparasitic medication—for treating skin cancers such as basal cell carcinoma, squamous cell carcinoma, and melanoma. Drawing from a compilation of anecdotal success stories, case reports, and preliminary scientific insights, we examine how this affordable, over-the-counter option might disrupt traditional dermatological approaches. While not a substitute for professional medical advice, these narratives highlight patient-driven innovations that challenge the status quo, prompting a closer look at ivermectin's multifaceted mechanisms and real-world applications.

Case Presentations

Case 12 - 2025: 69 year old man from Peru with Stage 4 Melanoma (Anorectal)

Dr William Makis shared on X.com in October 2025:

IVERMECTIN and MEBENDAZOLE Testimonial - 69 year old man from Peru with Stage 4 Melanoma (Anorectal) reports after 4 months - dramatic improvement in quality of life! One of the most incredible testimonials I have, all the way from PERU! STORY: 69 year old man from Peru with Stage 4 Melanoma (Anorectal). He was given a prognosis of 3-6 months In late May 2025 he started: Ivermectin Mebendazole (high dose) He had one immunotherapy treatment (Nivolumab) which he didn't tolerate due to side effects. RESULT after 4 months (shouldn't be alive): Not only was his tumor “visibly reduced in size” but the clinical improvements have been nothing short of miraculous. "Since mid-July, he has completely stopped using any pain medications or laxatives. He now experiences no pain and is able to have regular bowel movements without discomfort, with normal stool consistency." "General Condition and Improvement: Previously, my father was bedridden — he only got up to use the restroom and required assistance to walk. He wore adult diapers and had no appetite. Since mid-July, however, he has shown remarkable improvement: He has regained weight. His appetite has returned. No longer uses diapers. Walks independently. Even drives his car on his own without any issues. He reports no anal pain. NO ONCOLOGIST. NO CHEMO. NO RADIATION. NO IMMUNOTHERAPY (couldn't tolerate it).

Case 11 - 2025: 59 year old Michigan woman with Skin Cancer (SCC and BCC)

Shared by Dr William Makis (X.com) in October 2025:

IVERMECTIN and MEBENDAZOLE Testimonial - 59 year old Michigan woman with Skin Cancer (SCC and BCC) sees major improvements after 4 months

Skin cancer can be very frustrating as it comes back again and again and again. Do you know how modern Oncology deals with that? Cut. Cut. Cut. That's it. NOT if you are a member of the world's largest Ivermectin Cancer Clientele. NOT if you've come to me! STORY: 59 year old Michigan woman with Skin Cancer (SCC and BCC) In early March 2025 she started: Ivermectin 1mg/kg/day Fenbendazole 1000mg/day, then switched to Mebendazole 1000mg/day End of June 2025, annual scan revealed NO skin cancer recurrence. " (the dermatologist) Her yearly exam has always resulted in one or several areas being frozen or surgically removed, so having no action required was a feeling of success".

Case 10 - 2025: Metastatic Melanoma NRAS Variant, age 69, Male

Shared by Ben Fen in August 2025:

This Case Report of PC, as told by his wife, documents the case of a 69-year-old male, with Stage 4 metastatic melanoma who achieved a complete metabolic response. PC initiated treatment with fenbendazole, resulting in a significant partial response, including the resolution of multiple metastatic sites. The subsequent addition of combination immunotherapy (Nivolumab/Relatlimab) led to the complete resolution of all detectable disease. This case highlights a successful therapeutic sequence, demonstrating the profound anti-neoplastic effects of fenbendazole and its synergy with checkpoint inhibitors in achieving a durable, cancer-free outcome.

Clinical Timeline: Diagnosis, Treatment, and Response

Jan 2023: Diagnosis: Stage 4 metastatic melanoma confirmed. Widespread disease in clavicle, aorta, abdomen, leg, mediastinum, and a suspicious brain lesion.

Initiated Fenbendazole: 222 mg daily. PC begins self-directed therapy.

May 2024: PET-CT: Resolution of clavicular and mediastinal metastases. Persistent para-aortic disease (SUV max 7.04). Unremarkable brain CT.

Fenbendazole 222 mg daily. Significant partial response to fenbendazole monotherapy.

June 8, 2024: Genetic testing confirmed NRAS mutation, CDKN2A gene )p.M53l variant).

June 10, 2024: Blood Panel: Transient elevation of liver enzymes (ALT/AST).

Fenbendazole 222 mg daily. Liver enzyme elevation likely due to tumor lysis; therapy continued.

June 20, 2024: Dose Adjustment: Fenbendazole increased to 444 mg daily (222 mg twice per day). Fenbendazole Dose Escalation. Dose increased to drive further therapeutic response.

Sept 17, 2024: PET-CT: Resolution of cutaneous leg lesion. Further reduction in para-aortic node (SUV max 5.89). No new disease.

Fenbendazole 444 mg daily. Continued favorable response.

Blood Panel: Liver enzymes returned to normal range.
Fenbendazole 444 mg daily. Normalization confirms the transient nature of the enzyme elevation, ruling out hepatotoxicity.

Sept 20, 2024: Immunotherapy Initiated: Began combination therapy with Nivolumab/Relatlimab (monthly infusions).

Immunotherapy Introduced. Standard-of-care immunotherapy added to consolidate gains.

Jan 10, 2025: CT & PET Scans: No nodal or metastatic disease detected. Para-aortic node no longer avid (SUV max 2.3). Clear brain scan.

Immunotherapy complete. Complete Metabolic Response Achieved.

May 15, 2025: Follow-up: PC is active, in excellent health, and remains cancer-free. Immunotherapy-induced colitis fully resolved. No active cancer treatment.

Durable Complete Response.

Case Presentation and Clinical Course

Initial Diagnosis and Fenbendazole Monotherapy: In January 2023, a 69-year-old male (PC) with a 35-year history of surgically managed melanomas was diagnosed with Stage 4 metastatic disease. PET-CT imaging confirmed extensive metastases involving the left supraclavicular fossa, mediastinal lymph nodes, para-aortic arch, abdomen, a cutaneous leg lesion, and a brain lesion of high concern. PC commenced self-administered fenbendazole at 222 mg daily. Over the next 16 months, he achieved a significant partial response on fenbendazole monotherapy. A PET-CT in May 2024 confirmed the complete resolution of metastases in the left supraclavicular fossa and mediastinal nodal stations.

Dose Escalation of Fenbendazole and Continued Response: In June 2024, a routine blood panel revealed a transient elevation in liver enzymes (ALT/AST). This was interpreted as a consequence of tumor lysis rather than drug toxicity. The fenbendazole dose was confidently increased to 444 mg daily. By September 2024, follow-up imaging demonstrated further disease regression, including resolution of the cutaneous leg lesion and a decrease in the metabolic activity of the remaining para-aortic lymph node (SUV max reduced from 7.04 to 5.89). Concurrently, his liver enzymes had normalized, validating the decision to continue and escalate the fenbendazole dose.

Introduction of Immunotherapy and Complete Response: With the majority of the disease burden eliminated by fenbendazole, combination immunotherapy (Nivolumab/Relatlimab) was introduced in September 2024 to target the residual disease. PC experienced a significant adverse event of immunotherapy-induced colitis, which persisted for approximately eight months before resolving. Follow-up scans in January 2025 revealed a complete metabolic response. All evidence of nodal or metastatic melanoma was absent. The metabolic activity in the previously persistent para-aortic lymph node had fallen to background levels (SUV max 2.3). As of May 2025, PC remains in excellent health, active, and cancer-free.

Conclusions: The Foundational Role of Fenbendazole

The clinical timeline establishes that fenbendazole monotherapy was responsible for the substantial initial tumor debulking. By the time immunotherapy was introduced, the majority of the metastatic burden had resolved, indicating fenbendazole acted as the primary therapeutic agent in this case. This initial response likely created a more favorable tumor microenvironment for immunotherapy. By inducing immunogenic cell death through mechanisms such as microtubule disruption, fenbendazole enhanced the presentation of tumor neoantigens, effectively "priming" the remaining disease for a robust and complete response to checkpoint inhibition.

Tumor Lysis as the Potential Cause of Transient Liver Enzyme Elevation

The transient elevation of liver enzymes is attributed to the metabolic stress of processing significant tumor lysis, a phenomenon observed in other cases of effective fenbendazole treatment. The resolution of the transaminitis (liver enzyme fluctuation), even after a fenbendazole dose escalation, coincided directly with the reduction in overall tumor burden. This temporal relationship suggests that the enzymatic rise was a consequence of therapeutic efficacy, not drug-induced liver injury. The return of AST/ALT to within normal limits despite continued fenbendazole administration supports the assertion as well.

This case documents a complete and durable metabolic response in a patient with advanced metastatic melanoma. A sequential treatment protocol, initiating with fenbendazole to debulk the tumor followed by consolidation immunotherapy, proved to be a highly effective strategy. This outcome underscores the potent anti-neoplastic capability of fenbendazole and its synergistic potential with modern immunotherapies.

PC’s wife reports that he is presently a “box of birds” after coming through this experience in successfully eradicating his cancer.

Case 9: Ivermectin & Fenbendazole Testimonial - Stage 4 Malignant Melanoma

• Source: https://t.co/WGllfQFysg
• Description: Posted on March 29, 2025, by

  @MakisMD

  , this highlights an Australian man with Stage 4 malignant melanoma with metastases to multiple sites. He reportedly achieved a "cancer-free" status after 12 months using ivermectin and fenbendazole.

Case 8: Stage 4 melanoma with mets to lymph nodes

Shared by DavidCarl (X/Twitter):

"As I’ve told you, my wife had stage 4 melanoma with mets to lymph nodes. She started taking ivermectin before you released your protocols, 1mg/kg. Weeks later you published your protocols and I bumped her to 2mg/kg. I added 444 mg of fenbendazole. Her last pet scan was approximately 6 months where she was cancer free. Her oncologist was all smiles, but I never told him I was giving her the protocol. She continues to take .5mg/kg of ivermectin 6x week and 3x week of 444 mg fenbendazole. She was taking immunotherapy for about a year before I read about ivermectin. Her lesions were having moderate response to the immunotherapy per pet scans. After putting her on ivermectin, 45 days later with a pet scan she presented cancer free. We were blown away. I almost cried. Doctor this is the hope you’ve given us. Your stories continue to give my wife confidence. It is like a big dark cloud we lived with was lifted."

Case 7: Stage 3B Melanoma with liver failure

Shared by Dr William Makis (X/Twitter) - February 2025:

IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE Testimonial:

FROM THE BRINK OF DEATH - Stage 4 Melanoma patient with extensive liver metastases given 2-3 days to live! Survives and most metastases are gone! 

If you only read 1 of my testimonials EVER, make it this one.  Canadian patient had Stage 3B Melanoma 5 years prior. In Dec.2024, he presented to emergency in liver failure.

"He was told (by an Oncologist) Dec.2nd that he had 2-3 days to live and was in liver failure as his entire liver was consumed with tumors". 

(Diagnosis: Stage 4 Melanoma recurrence with extensive liver metastases & liver failure) “The only thing he (Oncologist) could suggest to try was Bractovi and Mektovi but has never given it to anyone with their liver in such bad shape – we are told that it is completely taken over with both cystic and solid lesions. Against our belief we were faced with a ‘try or die….” "He was given 1-2% chance with Braftovi/Mektovi so started that Dec.3rd" "I reached out to you shortly thereafter and started your protocol. The CT results from Jan.30th (2025) that I am sending you show significant regression or complete resolution!!!" 

Braftovi/Mektovi - 59 days 

Ivermectin - 43 days 

Mebendazole - 38 days 

Fenben - 28 days MAKIS IVERMECTIN CLINIC PROTOCOL Implemented: 

Ivermectin 1mg/kg/day (43 days) 

Mebendazole 400mg/day (38 days) 

Fenbendazole 444mg/day (28 days)

Yes, you read that correctly. This is what's called "weighing the risks and benefits".

CT RESULTS: "All previously detected hepatic lesions have markedly regressed or resolved." "Excellent response to the interval instituted treatment regime, where there has been marked regression of the metastatic liver disease with associated significant reduction in the associated hepatomegaly. "There has been significant regression of the metastatic lymphadenopathy of the root of the small bowel mesentery" "there has been complete resolution of the underlying anasarca and ascites" "There are presently no signs of acute intra-abdominal/pelvic process observed" ----- My Take… Do you know what is probably the single most frustrating question I get every day? “Is Fenbendazole safe? My doctor told me it will damage my liver!” "My doctor told me Fenbendazole will destroy my liver" Let me summarize: Stage 4 Melanoma patient with extensive liver metastases told he had 2-3 days left to live... in LIVER FAILURE...

Implemented a Protocol with Ivermectin, Fenbendazole and Mebendazole! 

And is alive 2 months later with all metastases either shrunk or gone! FROM THE BRINK OF DEATH… If anyone ever tells you that Fenbendazole or Mebendazole will damage your liver, know that they are lying to you, and if you want to, show them this story!

Case 6: Basal Cell Carcinoma (BCC)

In this December 2024 case report published by Canadian Oncologist Dr. William Makis, we note the pictorial resolution of basal cell cancer [BCC] to the point that the patient may have to cancel his appointment for a planned surgical removal. One cannot surgically remove a basal cell cancer [BCC] that no longer exists.

This gentleman reports he is a long-time reader of Dr. Makis and was particularly interested in his reports of Fenbendazole and Ivermectin. He contracted basal cell cancer on his face in February or March of 2024, and did what most of us would do - he booked an appointment with his GP in June 2024, apparently the first available.

The soonest he could get scheduled for the Dermatology referral was sometime in November. Having nothing to lose, he decided to apply Fenbendazole paste per the articles he had previously read, and to his pleasant surprise the persistent non-healing skin cancer of seven months began to shrink in size.

FenBen Treatment from September 25 through October 28, 2024

By the time of his November Dermatology appointment, there was very little to biopsy, yet it was done. He reports the Dermatologist was not the least bit interested in his tumor shrinkage with the Fenbendazole paste. Instead, the Dermatologist booked him for a tumor removal appointment three months later in February 2025.

The patient continued to apply the paste for the next month following the November biopsy, and here is what the BCC looked like as of December 6, 2024.

Result of FenBen Topical Treatment from September 25 through December 6, 2024

He writes,

“I’m still treating it once a day with Safeguard 10% Fenbendazole and it seems to still be improving. So I’m undecided about whether I need to have anything removed. I guess I’ll see how it goes over the next while. Maybe it’s deep into the tissue despite having improved the surface cells. No idea.”

Dr. Makis writes in response that patients who take matters into their own hands seem to do better.

Case 5:

source: https://substack.com/home/post/p-155091883

Case 4: Melanoma (Skin Cancer)

Shared by Dr William Makis (X/Twitter) - Last Edited: October 2024:

FENBENDAZOLE Testimonial in Stage 4 Melanoma Cancer patient - didn't listen to Oncologist's advice to stop Fenben, and is now cancer free.

There is a key lesson here. The Oncologist gave the opposite advice of what was good for the patient. That's because the Oncologist was following Cancer Guidelines set by Big Pharma (like Pfizer). If this patient had followed his Oncologist’s advice and stopped the Fenbendazole, he would still have active Stage 4 melanoma metastases with a much worse prognosis. Maybe he'd already be dead. How do you know if you have a good Oncologist? Ask them how many COVID-19 Vaccines they took! The only correct answer is "0".

Case 3: May, 2022 - Squamous Cell Carcinoma

In September 2021, I went to the cancer clinic to get my second PET scan done after receiving the news in March 2021 that I have been diagnosed with cancer, and learnt that day that my tumor has shrunk to half the size it first was. There were still signs of lymph nodes increasing or being classified as unknown results. I continued the use of the fenben protocol along with a whole bunch of other supplements to take on a daily basis, as within 5 months results improved in comparison to a whole year of fighting off the protocol before with little to non improvement in results. I strongly believe in this protocol and in case you wondered – I am not on any chemotherapy/radiation/immunotherapy or any other western medicine use – this is a full on natural and holistic journey I went on, and I am happy to share my current protocol with all cancer patients out there:

• Serrapeptase (at midnight)
• Vit D & K2, Tudca 500mg, Graviola 1ml (on an empty stomach)
• Varies supplementation with breakfast (like Vit C & B complex, probiotics, fish oil, curcumin, etc. along with fenben 888mg)
• Multi-vitamin, turkey tail extract, fenben 888mg, and B17 apricot seed (with dinner)
• Some more other supplements just before bed (like magnesium, Vit C, Graviola, high dose of melatonin, coffee enemas, etc)
• Detox baths (1 x week)
• Frequency music (before bed designed to kill cancer cells)
• Mainly following a plant-based diet
• Protein intake is limited to certain meats
• Fresh whole foods/vegetables
• Healthy fats only

I trust that this protocol I am following will guide a lot of people out of their state – just belief and trust the process along with the support from others who have been through this before. Good luck.

Case 2: October, 2022

In February and March of this year I was diagnosed with stage four melanoma. It had metastasized to my brain, lymph nodes, right lung, adrenal gland and right hip. My daughter pointed me to Joe’s story and this site. I started taking the fenbendazole protocol even before my oncologist gave me her treatment plan using Immuno therapy. The oncologist said that it had about a 30% success rate but not to expect any great results on the first scan after 4 treatments.

I had a PET scan last week and the results were almost too good to be true. Cancer basically gone. The tumor in my right lung had shrunk to less than half the size it was on the first PET scan. The uptake on that tumor decreased from 19.9 to 2.6. I was told by her that an uptake of less than 4.0 is no longer considered as cancerous.

I have been on the fenbendazole protocol for 166 days now. I received 4 immunotherapy injections using 2 different drugs. I can’t say for sure what definitively gave me these great results. Draw your own conclusions but I think the fenbendazole was largely responsible for the great results.

Case 1: January, 2022

At first me and my partner were unsure about trying alternative treatments in addition to the radiation my partner receives. With the help from a holistic healer and referrals from a couple of people in our community, we found out about the fenbendazole protocol and started to add the protocol along with a few other supplements to my partner’s daily intake/routine to aid in fighting the skin cancer on his neck.

Topical Ivermectin Will Completely Heal Skin Cancer - Dr William Makis

Valerie Anne Smith posted on X.com in October 2025:

"Topical Ivermectin Will Completely Heal Skin Cancer...The Lesion Will Change, Get Smaller & Fall Off Completely." "You Can Literally Use It For Any Inflammatory Or Autoimmune Skin Condition." "It Comes As A 1% Prescribed Cream Or Buy The Over The Counter 1.87% 'Horse Paste.' Ivermectin is an antiparasitic drug with anti-inflammatory, anti-viral, anti-bacterial & anti-tumor effects.

Topical Ivermectin has fantastic applications in the dermatology world because it heals the skin microbiome of parasites, bacteria, toxins & pathogens. While healing the gut microbiome is paramount from within by using nutrition to detoxify & heal deficiencies...topical Ivermectin cream works to heal the stubborn epidermis & dermis layers of the skin that may not respond to internal healing completely. Topical Ivermectin Has Shown To Be Effective At Healing The Following Skin Conditions: Basal Cell Carcinoma Squamous Cell Carcinoma Melanoma Cystic Acne Ringworm Scabies Demodex Skin Mites Perioral Dermatitis Pityrosporum Folliculitis Hookworms Lice Moles Warts Skin Tags Ringworm Candida Athlete's Foot Rosacea Eczema Psoriasis How To Use... Apply a pea sized or pencil eraser sized amount twice per day onto the area of concern. Purchasing Topical Ivermectin... Prescription: 1% Ivermectin Cream or Gel prescribed by your healthcare provider. Public Purchase: 1.87% Ivermectin Paste can be purchased in person at any veterinary or farm store. And it can be ordered online from many retail establishments such as Amazon. Ivermectin Paste For Melanoma https://frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.989167/full Ivermectin Clears Skin Cancers https://pmc.ncbi.nlm.nih.gov/articles/PMC7505114/ Ivermectin Use In Dermatology https://pmc.ncbi.nlm.nih.gov/articles/PMC8354388/ Speaker: Dr William Makis, MD

"Topical Ivermectin Will Completely Heal Skin Cancer...The Lesion Will Change, Get Smaller & Fall Off Completely."

"You Can Literally Use It For Any Inflammatory Or Autoimmune Skin Condition."

"It Comes As A 1% Prescribed Cream Or Buy The Over The Counter 1.87% 'Horse Paste.'… pic.twitter.com/wjTlz7eqFC

— Valerie Anne Smith (@ValerieAnne1970) October 30, 2025

Conclusion

The anecdotal evidence surrounding topical ivermectin for skin cancer paints an intriguing picture of a simple, low-cost intervention that may hold untapped potential in dermatology and oncology. From rapid lesion resolutions to remissions in advanced cases, these stories underscore the need for innovative thinking beyond traditional paradigms. Yet, as with any emerging therapy, caution is paramount—consulting healthcare professionals and prioritizing evidence-based research remains essential to separate hope from hype. Ultimately, if validated through rigorous studies, ivermectin could redefine accessible cancer care, empowering individuals to take proactive roles in their health journeys.